2 Reasons to be Optimistic About Biogen’s Alzheimer’s Drug
Biogen (NASDAQ: BIIB) shocked investors last year when it said it would submit its investigational Alzheimer's drug to the Food and Drug Administration for approval -- months after halting studies that showed the drug didn't work.
The biotech company explained its decision to file in early 2020 for regulatory approval, saying a look at broader data renewed its belief in aducanumab. The drug acts by binding to and eliminating beta amyloid, a protein that clings to neurons in the brains of Alzheimer's patients.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
